[go: up one dir, main page]

NO20034576L - [Dihydro-benzo[b] [1,4] diazepin-2-on-derivater som MGLUR2- antagonister II - Google Patents

[Dihydro-benzo[b] [1,4] diazepin-2-on-derivater som MGLUR2- antagonister II

Info

Publication number
NO20034576L
NO20034576L NO20034576A NO20034576A NO20034576L NO 20034576 L NO20034576 L NO 20034576L NO 20034576 A NO20034576 A NO 20034576A NO 20034576 A NO20034576 A NO 20034576A NO 20034576 L NO20034576 L NO 20034576L
Authority
NO
Norway
Prior art keywords
diazepin
benzo
dihydro
derivatives
mglur2 antagonists
Prior art date
Application number
NO20034576A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034576D0 (no
Inventor
Juergen Wichmann
Geo Adam
Erwin Goetschi
Vincent Mutel
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20034576D0 publication Critical patent/NO20034576D0/no
Publication of NO20034576L publication Critical patent/NO20034576L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20034576A 2001-04-12 2003-10-10 [Dihydro-benzo[b] [1,4] diazepin-2-on-derivater som MGLUR2- antagonister II NO20034576L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109125 2001-04-12
PCT/EP2002/003644 WO2002083652A1 (en) 2001-04-12 2002-04-02 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II

Publications (2)

Publication Number Publication Date
NO20034576D0 NO20034576D0 (no) 2003-10-10
NO20034576L true NO20034576L (no) 2003-11-12

Family

ID=8177126

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034576A NO20034576L (no) 2001-04-12 2003-10-10 [Dihydro-benzo[b] [1,4] diazepin-2-on-derivater som MGLUR2- antagonister II

Country Status (37)

Country Link
US (1) US6544985B2 (sk)
EP (1) EP1379511B1 (sk)
JP (1) JP4071115B2 (sk)
KR (1) KR100566171B1 (sk)
CN (1) CN1264825C (sk)
AR (1) AR035816A1 (sk)
AT (1) ATE299868T1 (sk)
AU (1) AU2002312788B2 (sk)
BG (1) BG108254A (sk)
BR (1) BR0208891A (sk)
CA (1) CA2442557C (sk)
CZ (1) CZ20033003A3 (sk)
DE (1) DE60205100T2 (sk)
DK (1) DK1379511T3 (sk)
EC (1) ECSP034797A (sk)
ES (1) ES2246012T3 (sk)
GT (1) GT200200073A (sk)
HR (1) HRP20030792A2 (sk)
HU (1) HUP0400851A3 (sk)
IL (2) IL157873A0 (sk)
JO (1) JO2285B1 (sk)
MA (1) MA27012A1 (sk)
MX (1) MXPA03009311A (sk)
MY (1) MY140271A (sk)
NO (1) NO20034576L (sk)
NZ (1) NZ528315A (sk)
PA (1) PA8543301A1 (sk)
PE (1) PE20021041A1 (sk)
PL (1) PL367064A1 (sk)
PT (1) PT1379511E (sk)
RU (1) RU2263112C2 (sk)
SI (1) SI1379511T1 (sk)
SK (1) SK13682003A3 (sk)
UY (1) UY27258A1 (sk)
WO (1) WO2002083652A1 (sk)
YU (1) YU79003A (sk)
ZA (1) ZA200307243B (sk)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60009116T2 (de) 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
MXPA04006322A (es) * 2001-12-27 2004-10-04 Taisho Pharmaceutical Co Ltd Derivados de 6-fluorobiciclo[3.1.0]hexano.
US7119196B2 (en) * 2002-03-28 2006-10-10 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
EP1925614A1 (en) * 2002-03-28 2008-05-28 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
SI1651234T1 (sl) * 2003-07-25 2008-02-29 Hoffmann La Roche Kombinacija antagonista mglur2 in inhibitorja ache za zdravljenje akutnih in/ali kronicnih nevroloskih motenj
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
MXPA06014809A (es) * 2004-06-21 2007-02-12 Hoffmann La Roche Derivados de pirazol-pirimidina.
BRPI0607927A2 (pt) 2005-02-11 2009-10-20 Hoffmann La Roche derivados de pirazol-pirimidina
DK1863818T3 (da) 2005-03-23 2010-05-10 Hoffmann La Roche Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
JP5237798B2 (ja) 2005-06-23 2013-07-17 アレイ バイオファーマ、インコーポレイテッド ベンズイミダゾール化合物の調製方法
KR101121292B1 (ko) 2005-09-27 2012-04-13 에프. 호프만-라 로슈 아게 Mglur2 길항제로서 옥사다이아졸일 피라졸로-피리미딘
GB0600228D0 (en) * 2006-01-06 2006-02-15 Fermentas Uab Inactivation method
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200808751A (en) * 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
MX2009002538A (es) 2006-09-20 2009-03-20 Hoffmann La Roche Derivados de 4-oxo-2,3,4,5-tetrahidro-benzo[b][1,4]diazepina.
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EP2137167B1 (en) 2007-04-19 2011-08-10 F. Hoffmann-La Roche AG Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
TWI475995B (zh) 2007-09-14 2015-03-11 Janssen Pharmaceuticals Inc 1’,3’-二取代-4-苯基-3,4,5,6-四氫-2h,1’h-〔1,4’〕聯吡啶基-2’-酮化物
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 1,3−二置換−4−フェニル−1h−ピリジン−2−オン
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
AU2008323287B2 (en) 2007-11-14 2011-07-14 Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 有害生物防除剤としての新規複素環式化合物
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
JP5790195B2 (ja) * 2011-06-22 2015-10-07 セントラル硝子株式会社 ピラゾール化合物の製造方法
US9193710B2 (en) 2011-08-29 2015-11-24 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
WO2014018979A1 (en) 2012-07-27 2014-01-30 The Broad Institute, Inc. Inhibitors of histone deacetylase
RU2015116749A (ru) 2012-10-23 2016-12-20 Ф. Хоффманн-Ля Рош Аг Антагонисты mglu2/3 для лечения аутических расстройств
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
ES2929906T3 (es) * 2012-12-28 2022-12-02 Crystalgenomics Inc Derivado de 2,3-dihidro-isoindol-1-ona como supresor de cinasa BTK, y composición farmacéutica que lo incluye
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EP3424535A1 (en) 2014-01-21 2019-01-09 Janssen Pharmaceutica NV Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
SG11201607267SA (en) 2014-03-07 2016-09-29 Biocryst Pharm Inc Human plasma kallikrein inhibitors
RU2016144702A (ru) * 2014-04-23 2018-05-24 Ф. Хоффманн-Ля Рош Аг Антагонисты mglu2/3 для лечения интеллектуальной недостаточности
WO2015191630A1 (en) * 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN108727345B (zh) * 2017-04-25 2023-06-27 广东东阳光药业有限公司 一种咪唑环中间体的制备方法
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN108586447B (zh) * 2018-01-19 2021-01-29 中国人民解放军第四军医大学 一种苯二氮杂卓化合物及其制备方法和应用
MY209362A (en) * 2019-06-06 2025-07-03 Arcus Biosciences Inc Processes for preparing aminopyrimidine compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU224435B1 (hu) * 1995-02-09 2005-10-28 EGIS Gyógyszergyár Rt. Benzodiazepin-származékok, eljárás előállításukra, alkalmazásukra és ezeket tartalmazó gyógyászati készítmények
SK283859B6 (sk) * 1995-02-09 2004-03-02 Egis Gy�Gyszergy�R Rt. 1-[2'-(Substituovaný)vinyl]-5H-2,3-benzodiazepínové deriváty, spôsob ich prípravy a medziprodukty na ich prípravu, liečivá ich obsahujúce a ich použitie
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
PL357418A1 (en) * 1999-10-15 2004-07-26 F.Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
DE60009116T2 (de) * 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten

Also Published As

Publication number Publication date
CA2442557C (en) 2008-12-23
JP4071115B2 (ja) 2008-04-02
AU2002312788B2 (en) 2005-11-10
MA27012A1 (fr) 2004-12-20
PL367064A1 (en) 2005-02-21
YU79003A (sh) 2006-05-25
HUP0400851A2 (hu) 2004-07-28
PE20021041A1 (es) 2002-11-19
IL157873A (en) 2008-11-26
MY140271A (en) 2009-12-31
CN1535266A (zh) 2004-10-06
EP1379511B1 (en) 2005-07-20
CN1264825C (zh) 2006-07-19
DE60205100T2 (de) 2006-06-01
ZA200307243B (en) 2004-12-16
ECSP034797A (es) 2003-12-01
HUP0400851A3 (en) 2010-03-29
ES2246012T3 (es) 2006-02-01
GT200200073A (es) 2002-11-07
DK1379511T3 (da) 2005-11-07
KR20030087076A (ko) 2003-11-12
HRP20030792A2 (en) 2005-10-31
NZ528315A (en) 2005-04-29
RU2263112C2 (ru) 2005-10-27
US6544985B2 (en) 2003-04-08
UY27258A1 (es) 2002-10-31
JP2004529925A (ja) 2004-09-30
AR035816A1 (es) 2004-07-14
US20020193367A1 (en) 2002-12-19
CA2442557A1 (en) 2002-10-24
RU2003130637A (ru) 2005-04-10
CZ20033003A3 (cs) 2004-05-12
PA8543301A1 (es) 2003-01-24
IL157873A0 (en) 2004-03-28
EP1379511A1 (en) 2004-01-14
BR0208891A (pt) 2004-04-20
PT1379511E (pt) 2005-10-31
MXPA03009311A (es) 2004-02-12
WO2002083652A1 (en) 2002-10-24
SI1379511T1 (en) 2005-10-31
HK1068888A1 (en) 2005-05-06
NO20034576D0 (no) 2003-10-10
SK13682003A3 (sk) 2004-07-07
BG108254A (bg) 2004-09-30
KR100566171B1 (ko) 2006-03-29
JO2285B1 (en) 2005-09-12
DE60205100D1 (de) 2005-08-25
ATE299868T1 (de) 2005-08-15

Similar Documents

Publication Publication Date Title
DK1379511T3 (da) Dihydro-benzo[b][1,4]diazepin-2-on-derivater som mGLuR2-antagonister II
NO20034496D0 (no) Dihydro-benzo[b][1,4]diazepin-2-on-derivater som MGLUR2- antagonister I
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
FR14C0066I2 (fr) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles
NO20014412L (no) Forbindelser nyttige som anti-inflammatoriske midler
DE60026169D1 (de) Selektive neurokinin-antagonisten
NO20011738D0 (no) Heterocyclylaminometyloksazolidinoner som antibakterielle midler
ATE326467T1 (de) Imidazo 1,2-aöpyridine
PT1210349E (pt) Pirazolo-¬4,3-d|-pirimidinas
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
NO20015668D0 (no) Substituerte imidazotiazoler som antidepressive midler
DK1181288T3 (da) Bicycliske oxazolidinoner som antibakterielle midler
DK0964863T3 (da) Oxazolidinoner som 5-HT2A-antagonister
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
PT1351959E (pt) Novos derivados de pleuromutilina
DK1261588T3 (da) Imidazolforbindelser som alfa2-adrenoceptorantagonister
DK1294729T3 (da) 2-aminoalkyl-thieno[2,3-d]pyrimidiner
PT1326866E (pt) 3,4-di-hidropirido[1,2-a]pirimidinas substituidas
NO20011309D0 (no) Benzotieno [3,2-c]pyridiner som<alfa>2-antagonister
DK1380585T3 (da) Pyrazolopyridinon som mellemprodukt
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
ES1047631Y (es) Dispositivo para la fabricacion de piezas modulares para la construccion.
SE9902902D0 (sv) New formulation
ITRM20000199A0 (it) Formulazione.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application